Corebridge Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Corebridge Financial’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-101,231	Closed	-$759K	–	327
2025 Q1	$759K	Sell	101,231 -1,500	-1%	-$12.1K	﹤0.01%	1391
2024 Q4	$773K	Sell	102,731 -7,755	-7%	-$58.9K	﹤0.01%	1455
2024 Q3	$840K	Sell	110,486 -681	-0.6%	-$5.18K	﹤0.01%	1450
2024 Q2	$687K	Buy	+111,167	New	+$613K	﹤0.01%	1531

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Corebridge Financial's BCRX Position: Q2 2025 in Review

Corebridge Financial sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 101,231 shares — an estimated $759K sold.

Corebridge Financial first reported a position in BCRX in Q2 2024 and held it in 4 quarters. The position peaked at $840K in Q3 2024. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

Corebridge Financial reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Corebridge Financial sold 101,231 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $759K.
Corebridge Financial first reported a position in BioCryst Pharmaceuticals in Q2 2024 and held it in 4 quarters.
Corebridge Financial's BioCryst Pharmaceuticals position peaked at $840K in Q3 2024.
294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.